CTLT - Catalent, Inc.
| Previous Close | 43.12 |
| Open | 42.83 |
| Bid | 0.00 x 800 |
| Ask | 45.00 x 900 |
| Day's Range | 40.59 - 43.11 |
| 52 Week Range | 29.23 - 46.43 |
| Volume | 739,836 |
| Avg. Volume | 911,921 |
| Market Cap | 5.923B |
| Beta (3Y Monthly) | 1.94 |
| PE Ratio (TTM) | 41.93 |
| EPS (TTM) | 0.97 |
| Earnings Date | Apr 29, 2019 - May 3, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 45.80 |
- Zacks•9 days ago
CTLT or NBIX: Which Is the Better Value Stock Right Now?
CTLT vs. NBIX: Which Stock Is the Better Value Option?
- Simply Wall St.•17 days ago
Is Catalent, Inc.’s (NYSE:CTLT) Balance Sheet A Threat To Its Future?
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Catalent, Inc. (NYSE:CTLT), with a market capitalization of US$6.2b, rarely draw their attention from the investing community.Read More...
- Business Wire•18 days ago
Catalent, Inc. to Present at the Barclays Global Healthcare Conference
Catalent, Inc. , the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Wetteny Joseph, Senior Vice President & Chief Financial Officer, will present at the Barclays Global Healthcare Conference at 2:35 p.m.
- Zacks•19 days ago
Champions Oncology (CSBR) Q3 Earnings: What's in Store?
During Champions Oncology's (CSBR) third-quarter fiscal 2019 conference call, investor focus will be on the company's progress with its Ex Vivo platform and services.
- Zacks•25 days ago
The Zacks Analyst Blog Highlights: Celgene, Charles River Laboratories International, Catalent and Aeterna Zentaris
The Zacks Analyst Blog Highlights: Celgene, Charles River Laboratories International, Catalent and Aeterna Zentaris
- Zacks•26 days ago
4 Drug Stocks to Buy Despite Price Hearing Woes
A burgeoning economy has necessitated diversification by the top players in the industry. Given such positives, any decision to lower drug prices will not hamper the space.
- Zacks•last month
Will Catalent Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Catalent.
- Business Wire•last month
Catalent Names Alessandro Maselli President and Chief Operating Officer
Catalent, Inc. (CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Senior Vice President, Global Operations Alessandro Maselli has been appointed President and Chief Operating Officer, a new position within Catalent. Maselli will continue to report to John Chiminski, Chair and CEO of Catalent.
- Zacks•last month
CTLT vs. NBIX: Which Stock Should Value Investors Buy Now?
CTLT vs. NBIX: Which Stock Is the Better Value Option?
- Markit•last month
See what the IHS Markit Score report has to say about Catalent Inc.
Catalent Inc NYSE:CTLTView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for CTLT with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding CTLT totaled $6.03 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Thomson Reuters StreetEvents•last month
Edited Transcript of CTLT earnings conference call or presentation 5-Feb-19 1:15pm GMT
Q2 2019 Catalent Inc Earnings Call
Motley Fool•2 months agoCatalent Inc (CTLT) Q2 2019 Earnings Conference Call Transcript
CTLT earnings call for the period ending December 31, 2018.
- Zacks•2 months ago
Catalent (CTLT) Beats Q2 Earnings and Revenue Estimates
Catalent (CTLT) delivered earnings and revenue surprises of 21.62% and 3.11%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Catalent: Fiscal 2Q Earnings Snapshot
On a per-share basis, the Somerset, New Jersey-based company said it had net income of 33 cents. Earnings, adjusted for one-time gains and costs, came to 45 cents per share. The results surpassed Wall ...
- Business Wire•2 months ago
Catalent, Inc. Reports Second Quarter Fiscal 2019 Results
SOMERSET, N.J.-- -- Q2'19 revenue of $623.0 million increased 3% as-reported, or 5% in constant currency, from the prior-year period. Q2'19 YTD revenue of $1,174.8 million increased 2% as-reported, or 4% in constant currency, from the prior-year period. Double-digit organic segment EBITDA growth within Biologics and Specialty Drug Delivery and Clinical Supply Services segments; Juniper acquisition ...
- Zacks•2 months ago
Analysts Estimate Catalent (CTLT) to Report a Decline in Earnings: What to Look Out for
Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•2 months ago
Investor Expectations to Drive Momentum within Cognizant Technology Solutions, Public Service Enterprise Group, Iron Mountain, Catalent, QuinStreet, and Entravision Communications — Discovering Underlying Factors of Influence
NEW YORK, Jan. 28, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Simply Wall St.•2 months ago
A Closer Look At Catalent, Inc.’s (NYSE:CTLT) Uninspiring ROE
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Read More...
- Business Wire•2 months ago
Catalent, Inc. Announces Second Quarter Fiscal Year 2019 Earnings Conference Webcast
Catalent, Inc. (CTLT) (“Catalent”), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, today announced that it will release financial results for the second quarter of fiscal year 2019 ended December 31, 2018, before the market open on Tuesday, February 5, 2019. Catalent invites all interested parties to listen to the webcast, which will be accessible through Catalent’s website at http://investor.catalent.com. A supplemental slide presentation will also be available in the “Investors” section of Catalent’s website prior to the start of the webcast.
- Associated Press•2 months ago
Catalent to expand Wisconsin biomanufacturing operation
MADISON, Wis. (AP) — A global biotechnology company plans to add more than 100 new jobs at its facility in southern Wisconsin.
- Business Wire•2 months ago
Catalent Invests $200 Million to Expand Biologics Capacity and Capabilities
Catalent, Inc. , the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced it has commenced a $200 million capital investment in its Biologics business to expand drug substance manufacturing capacity and drug product fill/finish capacity due to projected growth among existing and future customers.
- American City Business Journals•3 months ago
Stocks down in December for pharma firms in the Triangle
Pharmaceutical companies in the Triangle were far from exempt from a worldwide dive in stock prices, with some companies sliding more than 50 percent.
- Business Wire•3 months ago
Catalent, Inc. to Present at the 37th Annual J.P. Morgan Health Care Conference
Catalent, Inc. , the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that John Chiminski, Chairman & Chief Executive Officer, will present at the 37th Annual J.P.
